Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Saussele, Susanne, Hehlmann, Rüdiger, Fabarius, Alice, Jeromin, Sabine, Proetel, Ulrike, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Einsele, Hermann, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Oppliger Leibundgut, Elisabeth, Heim, Dominik, Krause, Stefan W., Hofmann, Wolf-Karsten, Hasford, Joerg, Pfirrmann, Markus, Müller, Martin C., Hochhaus, Andreas, Lauseker, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940636/
https://www.ncbi.nlm.nih.gov/pubmed/29479070
http://dx.doi.org/10.1038/s41375-018-0055-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940636/
https://www.ncbi.nlm.nih.gov/pubmed/29479070
http://dx.doi.org/10.1038/s41375-018-0055-7

Ejemplares similares